The TCIF at the Beth Israel Deaconess Medical Center (BIDMC) fills a major unmet need at Harvard Medical School and all of Massachusetts, namely, the cGMP manufacture and aseptic fill-finish of non-radioactive and radioactive pharmaceuticals to enable first-in-human trials of novel molecules. Construction of the facility was funded by an ARRA grant from the NIH and was completed in August of 2013.

The TCIF is a state-of-the-art 1,400 sq ft facility designed for the cost-efficient, time-efficient, and safe cGMP manufacturing and aseptic fill-finish of novel non-radioactive or radioactive in vivo diagnostic and therapeutic agents for cancer and other diseases.